Dr. RR Baliga's 'Podkast for the Kurious Doc'
A landmark study on transcatheter tricuspid valve replacement (TTVR) offers compelling real-world evidence 🫀 ✅ 98.4% procedural success ✅ Near-complete TR elimination (97.7% at 30 days) ✅ Significant improvement in symptoms & quality of life ⚠️ Trade-off: ~16% new pacemaker rate in device-naïve patients In an elderly, high-risk cohort, TTVR delivers what surgery often cannot—restoration without incision, relief without delay. A meaningful step forward in structural heart disease—where the right heart finally takes center stage ✨
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
A quiet shift, yet a profound one. 🧠 The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy. For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️ The implications extend beyond stroke—to a broader rethinking of thrombosis itself: can we uncouple clot from bleed? This study suggests we can. #StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
🧠 Brain metastases remain a clinical frontier—common, complex, and still lethal. In Science Signaling, Chafe et al. unpack the biology: Blood Brain Barrier traversal, metabolic rewiring, and immune evasion. Key insight: metastasis is not just spread—it is adaptation. From adenosine-driven immunosuppression to neuronal-like tumor states, new therapeutic doors are opening. Precision oncology must now think beyond the primary tumor. #BrainMetastases #Oncology #NeuroOncology #Immunotherapy #PrecisionMedicine
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
What if the roots of modern surgery were written over 2,000 years ago? 🩺📜 Meet —a pioneer whose Suśruta Saṃhitā laid the foundations of plastic surgery, cataract procedures, and structured medical training. From rhinoplasty to hands-on simulation using natural models, his approach was remarkably ahead of its time. A reminder that innovation is often rediscovery—and that the future of medicine is deeply anchored in its past. 🌍✨ #HistoryOfMedicine #Ayurveda #Surgery #MedicalEducation #Innovation
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
🧠💊 Stop. Test. Rethink. A compelling new study in JAMA shows that ~26% of adults ≥60 years can safely discontinue levothyroxine, maintaining normal thyroid function—especially those on low doses (≤50 μg/day). 📉 No meaningful decline in quality of life 📊 Clear dose-response signal ⚠️ Raises concerns about lifelong overtreatment The message is elegant: Not every prescription deserves permanence. Time to reassess, deprescribe, and individualize—particularly in our older patients. #Thyroid #Endocrinology #Deprescribing #Geriatrics...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
A fascinating step forward in Nature—where immunology meets cardiology. 🧬❤️ This study shows that engineered dendritic cells can locally reprogram the immune response, reduce fibrosis, and improve cardiac function—without systemic immunosuppression. The insight is simple, yet profound: 👉 Heart failure is not just hemodynamic—it is immunologic. From FAP-targeted delivery to checkpoint-mediated tolerance (PD-L1, CTLA4-Ig, IL-10), this work opens the door to a new therapeutic paradigm—precision immunotherapy for heart failure. 🚀 The seeds of...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
🧠⏳ Age. Biology. Truth. A compelling Perspective in the New England Journal of Medicine challenges one of medicine’s quiet assumptions: that age equals risk. Two patients may share a birth year—but not a biology. From epigenetic clocks to physiological reserve, the evidence is clear: chronologic age is an imperfect proxy for clinical decision-making ⚠️ The consequence? Missed prevention in the young, withheld therapy in the old. ✨ The opportunity? A shift toward biologically grounded, precision care—where treatment aligns not with years lived,...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉 A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects. 📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precision obesity therapeutics The future may not be “one drug fits all,” but one genome, one strategy.
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
Master athletes challenge one of medicine’s most elegant assumptions: that fitness always protects. In the Journal of the American College of Cardiology (JACC) consensus statement on athletes with abnormal cardiovascular findings, a paradox emerges—higher fitness, yet distinct patterns of risk: atrial fibrillation, coronary calcium, myocardial fibrosis. The lesson is not to discourage exercise—but to refine our lens. For the clinician: risk stratification must be individualized. For the athlete: performance and prudence must coexist. 🏃♂️ The heart...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
A compelling study in : sustained moderate-to-vigorous physical activity across midlife is associated with a ~50% reduction in all-cause mortality in women (target trial emulation). Not intensity, not intermittence—consistency is the signal. For clinicians, the prescription is enduring: move often, move steadily, move for life. 🏃♀️💓 #PLOSMedicine #PreventiveCardiology #LifestyleMedicine #HealthyAging
info_outline🧬 Apolipoprotein M (ApoM) is emerging as a key regulator of vascular biology.
ApoM, an HDL-associated lipocalin, transports sphingosine-1-phosphate (S1P) and selectively activates S1PR1 signaling in endothelial cells.
This pathway stabilizes the endothelial barrier, promotes nitric-oxide mediated vasodilation, and suppresses vascular inflammation.
Clinical studies increasingly link lower ApoM levels with cardiometabolic disease, CKD, and heart failure risk.
New therapies—including ApoM-fusion biologics and selective S1PR1 agonists—may harness this pathway for vascular protection.
The ApoM–S1P axis may represent a new frontier in precision cardiovascular medicine.